															_	
(PW FORM	epartn I PAT-	nent of Commerce	007	P &	yC35 =			Atty. Dkt. No.	M#			Clien	t Ref.			
INFORM	ATIO	N DISCLOSUR	EST	VIED N	ENT			Applicant	037003-0 : Anderso			1992	2 <b>-</b> 30-	0029CF	2	
BY APPL	ICA1	NT														
									08/921	·						
Date: Octo	har 1	4 2003	Page	1	of	2	1	Filing Dat Examiner				up Art U	lnit: 1	644		
	72	OCUMENTS	i ago			14		<u> </u>  Examiner	. Scriwaui	ion, K.	1010	up Ait C	111L 1	044		
Examiner'	(Ne)	Document	. 2000	Date	iodis.	Name	(audieta a	terentida (B., 1913)	\$20495 ((DA 360)	erit in the second	Class	s Sub	<u>,1, 0,156</u>	Filing	्रहे <b>प्रके</b>	
S		Number		MM/Y	YYY	ı	lame	of First Inv	rentor)		Olus	Clas		Date		
Initials*						<u> </u>					۸_			(if appropriat		
m1		5,648,267		07/19	97	Reff					<b>166</b>	320.	320.1			
	BR				1		war na kasa i			On		SYL,				
FOREIGN	PAT	ENT DOCUMEN	rs.	igeni. Sulva Seksa	i dhigasi				<i>````</i> }}	, °¢,	` <b>.</b> .	English	シ	Translati Readily	ion	
				Date Country MM/YYYY		try	Inventor Name		10,	CEAL		2000	Ma		•	
										TECH CENTE			T.:	Enclose No		
MS	-	0.405.000.04				w					<u>' 160</u>	Enclosed	No	Enclose	No	
רפיץ		0 125 023 A1	11/198		EP			lly, et al.				590p	┼	ļ	-	
	DR ER	0 125 023 B1 0 125 023 B2	11/198 03/200		EP EP		Cabilly, et al.						+	<u> </u>		
<del></del>	<del> </del>	0 123 023 B2 0 173 494 A2	03/200		EP		Cabilly, et al.  Morrison, et al.						┼─		┼	
	<del>                                     </del>	WO 88/04936	07/198		WO-			nson, et al.					╁	<u> </u>	Н	
	HR	110 00/04930	077100	, o	110		1400	Havin, ocur					+		-	
OTHER (I	<del>'</del>	ng in this order A	uthor	Title	L Period	ical Name	Date	a Portinen	t Pages d	to V			╁	<u> </u>	+-	
		Adams, R.A. e	t al., Dir	ect im	plantat	ion and se	lal tra	nsplantation	n of human		**************************************					
		Adams, Richar							<del></del>	erimenta	al		$\vdash$		H	
		investigation of hu														
		Appelbaum, F. Hodgkin's Lympho								f Non-			~ -	ļ		
MI		Armitage, J.O. lymphoma treated Cancer 50:1695 (*	with cy													
		Beulianne, G.L Nature 312:643 (D				functional	chima	neric mouse	human an	tibody.		`				
M1		Brunner, K.T. ε <sup>51</sup> Cr-labeled allogε 14:181-189 (1968	eneic ta	uantita rget ce	tive as ells <i>in v</i>	say of the l	ytic action by	tion of imm isoantibody	une lymph and drugs	oid cells s, <i>Immun</i>	on ology					
		Chomczynski, thiocyanate-pheno														
		-Eary, J.F. et al 1268 (1990).									57					
M)		Einfeld, D.A. e hydrophobic prote									1					
		Goldenberg, D lymphomas with ic (1991).									64					
4		Kaminski, M.G				otherapy o	f B-ce	ll lymphom	a with [ <sup>131</sup> l]	anti-B1	(anti-					

NL

11/24/2007

Mu I	Liu, A.Y. et al., Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20	T	T	T	Т
(17)	with Potent Fc-Dependent Biologic Activity. J. Immun. 139/10:3521-3526 (1987).				
	Marx, Antibodies made to order, Science 229 455 (August 1985).				T
	Morrison, S.L. et al., Chimeric human antibody molecules: Mouse antigen-binding demains with human constant region domains, PNAS 81:0851-0854 (November 1984).				
	Morrison, Transfectomas provide novel chimeric antibodies, Science 229.1202-1207 (September 1985).				Ī
	Münro, Uses of chimaeric antibodies, Nature 312:597 (December 1984).				
	Neuberger, M.S. et al., A hapten-specific chimaeric lgE antibody with human physiological effector function, Nature 314:268 (March 1985).				Γ
	Press-et al., Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas, Blood 69(2):584-591 (1987)				
Mil	Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." New England Journal of Medicine 329/17: 1219-12223 (1993).				
	Rress, O.W. et al., "Treatment of refractory non Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, J. Clin. Onc. 7/8:1027-1038 (1989)				
<i>δω</i> δ0	Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," Hum. Antibod. Hybridomas 2:84-93 (1991).				Γ
	Sahagan et al.; A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, J. Immunol. 137:1086-1074 (1986).				Г
K3)	Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, <i>Harvey Lectures</i> 69:125-143 (1974).		·		
VB1	Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).				
	Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, <i>Nucl. Med. Bio.</i> 18(6): 589-603 (1991).				
	Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, Hybridoma 5/1:517 (1986).				
	Tan et et., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, J. Immunol. 135:8564 (November 1985).	~ .		~	
,my	Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).	بتسخينه وأعطام			
M3/	Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, <i>J. Biol. Chem. 264(19)</i> :11282-11287 (1989).				
xaminer	Date Considered: 11/2	1/200	<u></u>		
EXAMINER:	Initial if citation considered, whether or not citation is in conformance with MPER 5 con. De-	1100			
in conforma	ince and not considered leabyte with the state of the comorniance with MPEP 9 809. Dray	v line thro	ough a	citation if	į

not in conformance and not considered. Include copy of this form with next communication to Applicant.

Internation Disclosure Stavement By Applicant: AnDerson et al.   Applica	FORM F To: U.S (PW FO	. Depar	tment T-144	of Commerce	DE O		OFFICE LE			Atty. Dkt. No.	M#		Client Ref.			
Applicant: ANDERSON et al.  Applicant: Anterior (Family Anderson)  Applicant: Anteri				\_		_	15.V				0275463		1992-30	-00	29CP2	
Appln. No.: 08/921,060   Filling Date: August 29, 1997   Examiner: R. Schwadron   Group Art Unit: 1644   U.S. PATENT DOCUMENTS   Document   Number   MM/YYYY   Mark 6,183,744 81   02/2001   GOLDENBERG   Class   Date   Date   Class   Date	INFOR	MATI	ON E	ISCLOSUR	E Ŝħ	TO SERVICE	ENT			Applicant	: ANDERSON	et al.				
Variable   Part   Par										Appin. No	o.: 08/921,060					
Date   December 3, 2003   Page   1   of   1	ŭ											1997				
Document Number   Name   Name   Class   Sub   Class   Date	Date: [	Decem	ber 3,	2003	Page	1	of	1		Examine	r: R. Schwadro	n Grou	up Art Uni	t: ′	1644	
Number	U.S. PA	TENT	DOC	UMENTS						_						
No.   1,3,744 B1   1,0/2001   GOLDENBERG								1		of First In	ventor)	Class	Class			
CR		m	AR	6,183,744 B1		02/20	001	GOL	DENBER	3						
DR   ER		W)		6,306,393 B1		10/20	001	GOL	DENBER	3					ļ	
FR   FR	<u> </u>							ļ	*				ļ			
FR   Document Number   Date   MM/YYYY   Country   Inventor Name   English   Abstract   Readily Available    GR	<u> </u>	<u> </u>						-	-				<del> </del>			
FOREIGN PATENT DOCUMENTS    Document Number   Date   Country   Inventor Name   English   Translation   Readily   Available	<u> </u>	 				-		╁					<u> </u>		<del></del> -	
Document Number Date MM/YYYY Country Inventor Name English Readily Readily Available  GR HR HR IR JR KR LR OTHER  MR Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 3, No. 1, Abstract No. 83.  NR Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, Proceedings of ASCO, Vol. 9, p. 271, Abstract No. 1051.  OR Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with 1131 MB-1 Monoclonal Antibody," The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting, p. 852, Abstract No. 622.  PR Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36, Abstract No. 66.  QR Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.	FORE	CNLDA		DOCUMENT	· C	<u> </u>						<u> </u>	<u> </u>	٠. –	<u></u>	
HR IR JR JR JR KR LR OTHER  MR Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 3, No. 1, Abstract No. 83.  NR Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, Proceedings of ASCO, Vol. 9, p. 271, Abstract No. 1051.  OR Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting, p. 852, Abstract No. 622.  PR Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36, Abstract No. 66.  OR Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR TR UR	FOREI	SIN PA	ICINI	Document	Date	YYY	Coun	itry	Inventor	Name					Readily	
IR  JR  JR  KR  LR  OTHER  MR Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 3, No. 1, Abstract No. 83.  NR Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, Proceedings of ASCO, Vol. 9, p. 271, Abstract No. 1051.  OR Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with 1131 MB-1 Monoclonal Antibody," The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting, p. 852, Abstract No. 622.  PR Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36, Abstract No. 66.  QR Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR  TR  UR			GR													
JR KR LR  OTHER  MR Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 3, No. 1, Abstract No. 83.  NR Kaminski, et al., "Radioimmunotetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, Proceedings of ASCO, Vol. 9, p. 271, Abstract No. 1051.  OR Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with 1131 MB-1 Monoclonal Antibody," The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting, p. 852, Abstract No. 622.  PR Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36, Abstract No. 66.  QR Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR UR			HR													
KR LR  OTHER  MR Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 3, No. 1, Abstract No. 83.  NR Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, Proceedings of ASCO, Vol. 9, p. 271, Abstract No. 1051.  OR Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting, p. 852, Abstract No. 622.  PR Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36, Abstract No. 66.  QR Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR  TR  UR			<u>IR</u>						ļ							
TR  OTHER  OTHER  MR  Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 3, No. 1, Abstract No. 83.  NR  Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, Proceedings of ASCO, Vol. 9, p. 271, Abstract No. 1051.  OR  Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting, p. 852, Abstract No. 622.  PR  Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36, Abstract No. 66.  QR  Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR  Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR  TR  UR		ļ <u>.</u>					<u> </u>									
OTHER  MR Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 3, No. 1, Abstract No. 83.  NR Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, Proceedings of ASCO, Vol. 9, p. 271, Abstract No. 1051.  OR Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting, p. 852, Abstract No. 622.  PR Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36, Abstract No. 66.  QR Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR  TR  UR		<u> </u>					-		<u> </u>	<del></del>				L	ļ	↓
MR Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 3, No. 1, Abstract No. 83.  NR Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, Proceedings of ASCO, Vol. 9, p. 271, Abstract No. 1051.  OR Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting, p. 852, Abstract No. 622.  PR Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36, Abstract No. 66.  QR Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR  UR		<u> </u>	LR	<u> </u>	<u> </u>		<u> </u>	<del></del>	<u> </u>				ļ	<u> </u>	<u> </u>	
B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, Proceedings of ASCO, Vol. 9, p. 271, Abstract No. 1051.  OR Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting, p. 852, Abstract No. 622.  PR Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36, Abstract No. 66.  QR Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR  UR	OTHER		MR	Doses of 131	-I MB-	1 Anti	munot body,"	herap 1990	oy of Adva , A <i>ntibody</i>	nced B-Ce Immunoc	ell Lymphoma w onjugates, and i	ith Non I	Bone Mari armaceuti	row	Ablatives, Vol. 3	)
Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting, p. 852, Abstract No. 622.  PR Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36, Abstract No. 66.  QR Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR  TR  UR				B-Cell Lymph 1051.	oma V	Vith 1:	31-I MI	B-1 A	ntibody," 1	990, <i>Proc</i>	eedings of ASC	O, Vol. 9	), p. 271, <i>i</i>	Abs	stract No	of ).
Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36, Abstract No. 66.  QR Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR  TR  UR			OR	Wahl, et al., " Journal of Nu	Radioi <i>clear I</i>	mmur <i>Nedici</i>	nothera ne: Pro	apy of	B-Cell Ly lings of the	mphoma v 37 <sup>th</sup> <i>Ann</i>	with I131 MB-1 N <i>ual Meeting</i> , p.	Monocloi 852, Abs	nal Antibo stract No.	dy, 62:	" <i>The</i> 2.	
Lymphoma," 1990, Blood, Vol. 76, No. 10, p. 355a, Abstract No. 1409.  RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR  TR  UR			PR	Lymphoma,"	1990, $\lambda$	ase I Antibo	Trial R	Result: muno	s of 131-I conjugates	MB-1 Anti s, and Rad	body Radioimm diopharmaceutio	unothera als, Vol.	apy (RAIT 4, No. 1,	) of p. 3	B-Cell 36,	
RR Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp. 1696-1711.  SR TR UR			QR	Kaminski, et a Lymphoma,"	al., "Ph 1990, <i>i</i>	ase I Blood	Evalua Vol. 7	ation o	of 131-I MI . 10, p. 35	3-1 Antibo 5a, Abstra	ody Radioimmun act No. 1409.	otherapy	(RIT) of	B-(	Cell	
SR TR UR		4	RR	Kaminski, et a	al., "lm	aging	, Dosir	netry,	and Radi	oimmunot	herapy With Iod	ine 131- 0, No. 1	Labeled A	nti 6-1	-CD37 711.	
UR			SR													
			TR		-										· · · · · ·	
Examiner \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \			UR													
Date Considered: 11 (24) 200 7	Examine	er (	1	1		_				Date Con	sidered: \\ \2	y h	ار <sup>ور</sup>			

FORM PTO-1449 (modified) To: U.S. Department of Commerce									M#		Client Ref.				
	. Department RM PAT-1449							Dkt. No.							
	ind Trademar														
									0275463	1992-30-0029CP2					
INFOR	MATION E	ISELIOS VERE	STA	TEME	ENT			Applicant:	ANDERSON e	al.					
	PLICANT			_											
	MAR 1 8 2004 🗒								Appln. No.: 08/921,060						
	\-	•	_	Filing Date	e: August 29, 19	97									
Date: N	March 18, 20	OF AN	1	of		Examiner	Schwadron, R.	Gro	up Art Unit:	1644					
U.S. PA	ATENT DOC	UMENTAGENT						-			-				
Examiner's		Document		Date		Nam	е		C	Class	Sub	Filing			
Initials*		Number		MM/Y	YYY	(Fam	ily Name	of First Inv	entor)		Class	Date			
	`AR-	5,595,721		01/19	97	KAM	INSKI								
MSI	BR	5,439,665		08/19	95	HAN	SEN								
MI	CR	RE 38,008		02/20	03	ABR	AMS				_				
	~-DR	<del>5,736,</del> 137		04/19	98	AND	ERSON-				<u> </u>	_			
V3)	ER	5,776,456		07/19	98	AND	ERSON								
	FR	5,843,439		12/19	98	AND	ERSON								
	GR	6,399,061		06/2002		AND	ERSON								
4	HR	6,682,734		01/20	04	ANDERSON									
FOREIGN PATENT DOCUMENTS															
		Document Number	Date MM/\	^^^	Coun	try	Inventor I	iame			English Abstract	Transla Readil Availal	у		
	IR	WO 94/11026	05/19	94	PCT		ANDERS	ON							
	JR						8								
	KR														
	LR														
	MR							-							
OTHER	₹	· · · · · · · · · · · · · · · · · · ·													
•	NR	Grossbard M.L 80:863-878.	, et a	1., "M	poeto	nalar	ntibody-ba	sed the <del>ra</del> p	ies of leukemia.	and lyn	aphoma," E	100d, 19	92,		
•	m OR	Tedder T.F., el activation of hu	t al., "/ ıman	Antibo B lym	dies re	eactiv es," <i>E</i>	e with the Eur J Imma	B1 molecturol, 1986,	ule inhibit cell cyc , 16(8):881-87.	le pro	gression bu	t not			
									oding a new mou						
*	My								0) antigen, and l	ocaliza	tion of the	gene to			
	0.0	chromosome 1	9, 31	mmui	101, 19	00, 14	41(12):430	38-94.	<del></del>						
ļ ———	QR RR		•								***				
			<del></del> .												
	SR														
	TR	······													
	UR									_					
Examine	er V	L 2						Date Cons	sidered:	124	12007				
*EXAMI	INER: Initia	al if citation cons	idered	whetl	ner or r	not cita	ation is in c	onformance	with MPEP § 609				if not		
un confor	mance and n	ot considered. In	clude (	сору о	f this fo	orm wi	th next con	nmunication	to Applicant.						

To: U.S.	TO-1449 (mod Department o RM PAT-1449) nd Trademark	f Commerce		/ • MA	Y 2 6	ح» 2004	A CE	Atty. Dkt. No.	M#		Client Ref.	<del></del>		
				(FI)		ato	7		0275463		1992-30-	00:	29CP2	
	nd Trademark	SCLOSUR	E STA	TEM	ERAPE	MARIE		Applicant	: ANDERSO	N et al.				
								Appln. No	o.: 08/921,06	0				
									te: August 29					
Date: N	1ay 26, 2004		Page	1	of	1	7		r. R. Schwad		up Art Unit	t: 1	644	
	TENT DOCU	MENTS												
Examiner's		Document		Date		Nam	ie			Class	Sub		Filing	
Initials*		Number		MM/	<u> </u>	(Fan	nily Name	of First In	ventor)		Class		Date	
	AR					<u> </u>								
	BR	ļ				<u> </u>								
	CR					<u> </u>					<u> </u>			
	DR	ļ			<del></del>	ļ	<del>,</del>							
	ER			ļ		<del> </del>					<del> </del>			
	FR	-				├					<u> </u>			
	GR HR			ļ		<del> </del>			<del> </del>		1			
FOREIG		OCUMENT				<u> </u>		.***			<u></u>			
FOREIC	ON PATENT I	Document	<del></del>		Coun	tn/	Inventor	Nama			English		Translati	
		Number	MM/Y	<b>YYY</b>	Coun	u y	inventor	ivaine			Abstract		Readily Available	
	IR		ļ		ļ									Ш
	JR				ļ							_	<del></del>	
	KR		<u> </u>		<b></b>		ļ				1	_		
	LR	<b></b>	ļ		ļ		<del> </del>			••		_		$\sqcup$
	MR				<del> </del>		ļ	ā				_		╀┦
	NR OR	<u> </u>	<del> </del>		<del> </del>						-	_		╀┦
	OR PR		<del> </del>		<del> </del>						-	-		$\vdash$
OTHER		<u> </u>	<u> </u>	<del></del>	<u> </u>		<u></u> _							ᆜ
V13 )	QR	Idec Pharm 2003).	aceuti	cals v	Corix	a Coi	p., Case	No. 01-163	7-IEG [Doc. I	los. 486, s	584] (S.D.	Са	I. Oct. 1	4,
WH	RR	Biogen Ideo 2004).	v. Co	rixa C	orp., C	ase I	No. 01-16	37-IEG [Do	oc. Nos. 635,	662, 486]	(S.D. Cal.	Jar	n. 22,	
	SR													
	TR	ļ												
	UR													
	VR													_
	WR													,
	XR													
	YR						,						<del></del>	
	ZR								<del></del>					_
	AAR							·					<del>-</del>	
Examine		<u> </u>	$\overline{}$					Date Con	sidered:	1 . 1	رنہ ک			
*EV * * * * *	V ~		<u></u>	$\geq$				L		1/24/2	-			
*EXAMII	NEK: Initial mance and not	ii citation con	sidered	, whet	ner or r	ot cit	ation is in (	contormanc	e with MPEP §	609. Draw	line throug	h c	itation if	not

30398286v1